Concepedia

Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light

Mark HJ Wessels, Zoë YGJ van Lierop, Samantha Noteboom, Eva Strijbis, Johannes A. Heijst, Zoé L. E. van Kempen, Bastiaan Moraal, Frederik Barkhof, Bernard M.J. Uitdehaag, Menno M. Schoonheim,

Multiple Sclerosis Journal · 2023 · 13 citations · 28 references

DOIFull text

Open access

Abstract

sGFAP levels related to MRI markers of neuroinflammation and neurodegeneration.

References

28

UniProt: the universal protein knowledgebase in 2021

Alex Bateman, María Martin, Sandra Orchard et al. · Nucleic Acids Research · 2020 · 6.8K citations · Full text

, , +20

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

Chris H. Polman, Paul O’Connor, Eva Havrdová et al. · New England Journal of Medicine · 2006 · 3.3K citations · Full text

Serum GFAP as a biomarker for disease severity in multiple sclerosis

Ahmed Abdelhak, André Huss, Jan Kassubek et al. · Scientific Reports · 2018 · 269 citations · Full text

Fast and sequence-adaptive whole-brain segmentation using parametric Bayesian modeling

Oula Puonti, Juan Eugenio Iglesias, Koen Van Leemput · NeuroImage · 2016 · 252 citations · Full text

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels

Ali Manouchehrinia, Fredrik Piehl, Jan Hillert et al. · Annals of Clinical and Translational Neurology · 2020 · 232 citations · Full text